Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients
Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients With Hepatitis B Virus Infection
Sponsor: Peking University
Listed as NCT02108444, this observational or N/A phase trial focuses on Hematologic Diseases and Hepatitis and remains completed. Sponsored by Peking University, it has been updated 10 times since 2007, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Aug 2017 — Apr 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE4
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University
For direct contact, visit the study record on ClinicalTrials.gov .